The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective
| Autor: | Mohan Bajranglal Agarwal, Manthanathu Joseph John, Punit Jain, Ashok Kumar Vaid, Ajay Bapna, Maheboob Basade, Palanki Satya Dattatreya, Anupam Chakrapani, Vijay Ramanan, R. Varadarajan, Murali Subramanian, Chirag Aniruddha Shah, Narayanakutty Warrier, Subhaprakash Sanyal, Tyavanagi Shankarmurthy Ashwin, Nagendra Ramanjinappa |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Indian Journal of Medical and Paediatric Oncology. |
| ISSN: | 0975-2129 0971-5851 |
| Popis: | Management of chronic myeloid leukemia (CML) has been transformed by the use of tyrosine kinase inhibitors (TKIs). Presently in India, five TKIs are approved for the management of CML with distinct safety profiles. The selection of TKIs for chronic phase (CP)-CML patients is based on treatment goals, underlying comorbidities, and specific TKI toxicity profiles. Bosutinib is one of five TKIs indicated for the first-line treatment of CP-CML and patients with intolerance or resistance to prior TKI therapy. It possesses a distinct safety profile among other TKIs, with less cardiovascular adverse events (AEs), albeit the liver-related and gastrointestinal AEs have higher occurrence. The safety and efficacy of bosutinib have been examined in clinical trials; however, there is a paucity of data from Asia. A virtual expert panel meeting was convened to gather expert opinion from India on the selection of bosutinib as a treatment choice for patients with CP-CML. This is a white paper document drafted with the help of an expert panel of 14 oncologists and hematooncologists from India on bosutinib use in CP-CML. The experts concurred that bosutinib has proven efficacy for CP-CML in global randomized clinical trials and is well suited for CP-CML patients with existing cardiovascular comorbidities. However, it was not recommended for patients with gastrointestinal, pancreatic, or renal abnormalities. This review aims to put forth expert opinion and guidance document on key considerations for CP-CML clinical decision-making in India. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|